Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 181 Colorectal Neoplasms 144 Stomach Neoplasms 90 Rectal Neoplasms 90 Pancreatic Neoplasms 74 Neoplasm Metastasis 60 Neoplasms 48 Colonic Neoplasms 40 Esophageal Neoplasms 31 Gallbladder Neoplasms 18 Biliary Tract Neoplasms 17 Bile Duct Neoplasms 17 Carcinoma, Hepatocellular 15 Triple Negative Breast Neoplasms 13 Cholangiocarcinoma 12 Adenocarcinoma 12 Unspecified Adult Solid Tumor, Protocol Specific 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Liver Neoplasms 10 Breast Neoplasms, Male 10 Adenocarcinoma Of Esophagus 10 Squamous Cell Carcinoma of Head and Neck 9 Head and Neck Neoplasms 9 Gastrointestinal Neoplasms 9 Carcinoma, Renal Cell 8 Carcinoma, Non-Small-Cell Lung 8 Brain Neoplasms 7 Prostatic Neoplasms 6 Ovarian Neoplasms 6 Uterine Cervical Neoplasms 5

Interventions

Radiotherapy 1 Nivolumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Tumors × Capecitabine × Clear all

NCT03781362 2022-07-20

Study of CPI-100 in Patients With Advanced Tumors

Coordination Pharmaceuticals, Inc.

Phase 1 Completed

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡